Furthermore, the final presentation regarding upli
Post# of 148171
(Total Views: 473)
Posted On: 12/11/2020 12:23:48 PM
Quote:
Furthermore, the final presentation regarding uplisting to NASDAQ was downright discouraging, not just disappointing.
For a long time now I've said that drug approval would be necessary to NASDAQ. Either revenue or projected revenue sufficient for one years expenses is needed to list on NASDAQ. That is not in the NASDAQ listing guide but it is essential to all new listings on NASDAQ.
No need to be discouraged or disappointed if you know what's actually going on.
(2)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼